Published in Curr Drug Metab on April 01, 2007
Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol (2007) 2.19
Induction of IDO by bacille Calmette-Guérin is responsible for development of murine depressive-like behavior. J Immunol (2009) 1.77
Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev (2008) 1.68
Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol (2010) 1.29
Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrob Agents Chemother (2009) 1.16
B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3-dioxygenase. Proc Natl Acad Sci U S A (2010) 1.15
Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. Immunotherapy (2009) 1.10
The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer. J Transl Med (2009) 1.08
Dendritic cells as targets for therapy in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.02
Ig-like transcript 7, but not bone marrow stromal cell antigen 2 (also known as HM1.24, tetherin, or CD317), modulates plasmacytoid dendritic cell function in primary human blood leukocytes. J Immunol (2013) 1.02
CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J Immunol (2011) 1.01
Overactivation of plasmacytoid dendritic cells inhibits antiviral T-cell responses: a model for HIV immunopathogenesis. Blood (2011) 1.01
Cancer: Why tumours eat tryptophan. Nature (2011) 0.99
Plasmacytoid dendritic cells in HIV infection. Adv Exp Med Biol (2013) 0.90
Indoleamine 2,3-dioxygenase overexpression causes kynurenine-modification of proteins, fiber cell apoptosis and cataract formation in the mouse lens. Lab Invest (2009) 0.87
Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it? J Intern Med (2009) 0.87
Examining the relationship between diet-induced acidosis and cancer. Nutr Metab (Lond) (2012) 0.84
Effect of immunoglobin-like transcript 7 cross-linking on plasmacytoid dendritic cells differentiation into antigen-presenting cells. PLoS One (2014) 0.81
Plasmacytoid dendritic cells: development, functions, and role in atherosclerotic inflammation. Front Physiol (2014) 0.79
IDO-orchestrated crosstalk between pDCs and Tregs inhibits autoimmunity. J Autoimmun (2016) 0.78
CpG Type A Induction of an Early Protective Environment in Experimental Multiple Sclerosis. Mediators Inflamm (2017) 0.75
IDO1 and TGF-β Mediate Protective Effects of IFN-α in Antigen-Induced Arthritis. J Immunol (2016) 0.75
Indoleamine 2,3-dioxygenase in human hematopoietic stem cell transplantation. Int J Tryptophan Res (2010) 0.75
Natural killer cells: characteristics and regulation of activity. Immunol Rev (1979) 3.14
T cell apoptosis by tryptophan catabolism. Cell Death Differ (2002) 3.07
Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance. Infect Immun (1991) 2.46
Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J Exp Med (1996) 2.41
Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis. J Exp Med (1992) 2.37
CD4+ subset expression in murine candidiasis. Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance. J Immunol (1993) 2.30
Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. Eur J Immunol (1993) 2.05
Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect Immun (1986) 1.86
An immunoregulatory role for neutrophils in CD4+ T helper subset selection in mice with candidiasis. J Immunol (1997) 1.76
IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol (2010) 1.76
IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. J Immunol (1994) 1.75
Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. J Immunol (1994) 1.72
Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. J Immunol (1997) 1.68
IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. Immunity (1998) 1.64
Interleukin-12 in infectious diseases. Clin Microbiol Rev (1997) 1.63
Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immun (1997) 1.61
Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J (2003) 1.58
Role of L3T4+ lymphocytes in protective immunity to systemic Candida albicans infection in mice. Infect Immun (1989) 1.56
IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2,3-dioxygenase. J Immunol (2001) 1.46
Hemisection and vital treatment of a fused tooth--literature review and case report. Endod Dent Traumatol (1997) 1.44
Correlation between in vivo and in vitro studies of modulation of resistance to experimental Candida albicans infection by cyclophosphamide in mice. Infect Immun (1983) 1.43
T helper cell type 1 (Th1)- and Th2-like responses are present in mice with gastric candidiasis but protective immunity is associated with Th1 development. J Infect Dis (1995) 1.41
Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis (1998) 1.39
Platelet radiolabelling with 111 Indium for in vivo studies: a methodological reappraisal. Nucl Med Biol (1995) 1.38
Interleukin-12 but not interferon-gamma production correlates with induction of T helper type-1 phenotype in murine candidiasis. Eur J Immunol (1994) 1.33
T cell subsets and IFN-gamma production in resistance to systemic candidosis in immunized mice. J Immunol (1990) 1.29
Antifungal type 1 responses are upregulated in IL-10-deficient mice. Microbes Infect (1999) 1.27
Interleukin-4 and -10 exacerbate candidiasis in mice. Eur J Immunol (1995) 1.27
Rapid in vivo assay of mouse natural killer cell activity. J Natl Cancer Inst (1979) 1.26
Experimental model of type IV Streptococcus agalactiae (group B streptococcus) infection in mice with early development of septic arthritis. Infect Immun (1990) 1.25
CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J Immunol (2001) 1.25
Protective immunity induced by low-virulence Candida albicans: cytokine production in the development of the anti-infectious state. Cell Immunol (1989) 1.21
Natural cell-mediated cytotoxicity against Candida albicans induced by cyclophosphamide: nature of the in vitro cytotoxic effector. Infect Immun (1983) 1.20
Cytotoxic effector cells with the characteristics of natural killer cells in the lungs of mice. Int J Cancer (1980) 1.20
Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans. Mucosal Immunol (2009) 1.20
Gamma interferon modifies CD4+ subset expression in murine candidiasis. Infect Immun (1992) 1.19
Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis (1999) 1.19
Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J Infect Dis (1994) 1.19
Iron overload alters innate and T helper cell responses to Candida albicans in mice. J Infect Dis (1997) 1.19
Immunomodulation by a low-virulence, agerminative variant of Candida albicans. Further evidence for macrophage activation as one of the effector mechanisms of nonspecific anti-infectious protection. J Med Vet Mycol (1988) 1.18
Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans. Antimicrob Agents Chemother (1985) 1.18
In vivo natural reactivity of mice against tumor cells. Int J Cancer (1980) 1.16
IFN-gamma is required for IL-12 responsiveness in mice with Candida albicans infection. J Immunol (1998) 1.12
IFN-gamma inhibits presentation of a tumor/self peptide by CD8 alpha- dendritic cells via potentiation of the CD8 alpha+ subset. J Immunol (2000) 1.10
Experimental model of intracerebral infection with Cryptococcus neoformans: roles of phagocytes and opsonization. Infect Immun (1992) 1.10
IL-10 is required for development of protective Th1 responses in IL-12-deficient mice upon Candida albicans infection. J Immunol (1998) 1.09
Role of mannoprotein in induction and regulation of immunity to Cryptococcus neoformans. Infect Immun (2001) 1.08
Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma. J Immunol (2001) 1.07
Course of primary candidiasis in T cell-depleted mice infected with attenuated variant cells. J Infect Dis (1992) 1.07
Defective co-stimulation and impaired Th1 development in tumor necrosis factor/lymphotoxin-alpha double-deficient mice infected with Candida albicans. Int Immunol (1998) 1.07
Intracerebral transfer of an in vitro established microglial cell line: local induction of a protective state against lethal challenge with Candida albicans. J Neuroimmunol (1991) 1.07
Impaired antifungal effector activity but not inflammatory cell recruitment in interleukin-6-deficient mice with invasive pulmonary aspergillosis. J Infect Dis (2001) 1.06
Severity of group B streptococcal arthritis is correlated with beta-hemolysin expression. J Infect Dis (2000) 1.05
IL-9 protects mice from Gram-negative bacterial shock: suppression of TNF-alpha, IL-12, and IFN-gamma, and induction of IL-10. J Immunol (2000) 1.05
Chronic granulomatous disease. Cell Mol Life Sci (2009) 1.05
Biological role of Th cell subsets in candidiasis. Chem Immunol (1996) 1.04
Phagocytic killing of Candida albicans by different murine effector cells. Sabouraudia (1983) 1.04
TGF-beta is important in determining the in vivo patterns of susceptibility or resistance in mice infected with Candida albicans. J Immunol (1995) 1.03
Interleukin-6 (IL-6) prevents activation-induced cell death: IL-2-independent inhibition of Fas/fasL expression and cell death. Blood (1998) 1.02
Macrophage colony-stimulating factor in murine candidiasis: serum and tissue levels during infection and protective effect of exogenous administration. Infect Immun (1991) 0.99
Candida albicans-specific Ly-2+ lymphocytes with cytolytic activity. Eur J Immunol (1991) 0.98
A radiolabel release microassay for phagocytic killing of Candida albicans. J Immunol Methods (1982) 0.98
Using an ancient tool for igniting and propagating immune tolerance: IDO as an inducer and amplifier of regulatory T cell functions. Curr Med Chem (2011) 0.97
Anti-Candida resistance in the mouse brain and effect of intracerebral administration of interleukin 1. J Gen Microbiol (1991) 0.97
Initiation of T-helper cell immunity to Candida albicans by IL-12: the role of neutrophils. Chem Immunol (1997) 0.95
Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo. J Immunol (2000) 0.94
Mucosal and systemic T helper cell function after intragastric colonization of adult mice with Candida albicans. J Infect Dis (1993) 0.94
Natural killer cells do not play a dominant role in CD4+ subset differentiation in Candida albicans-infected mice. Infect Immun (1993) 0.93
Involvement of host macrophages in the immunoadjuvant activity of amphotericin B in a mouse fungal infection model. J Antibiot (Tokyo) (1986) 0.93
Anticryptococcal resistance in the mouse brain: beneficial effects of local administration of heat-inactivated yeast cells. Infect Immun (1994) 0.92
IL12 in Candida albicans infections. Res Immunol (1996) 0.90
Autocrine IL-12 is involved in dendritic cell modulation via CD40 ligation. J Immunol (1999) 0.88
Intraindividual comparative animal study of alpha- and beta-tricalcium phosphate degradation in conjunction with simultaneous insertion of dental implants. J Craniofac Surg (2001) 0.88
CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide. Eur J Immunol (1995) 0.86
Neutrophils and the adaptive immune response to Candida albicans. Res Immunol (1997) 0.84
IL-12 acts selectively on CD8 alpha- dendritic cells to enhance presentation of a tumor peptide in vivo. J Immunol (1999) 0.83
Cellular mechanisms underlying the adjuvant activity of Candida albicans in a mouse lymphoma model. Int J Cancer (1982) 0.83
A low virulent strain of Candida albicans enhances brain anticryptococcal defenses: characterization of the local immune reaction by RT-PCR and histochemical analysis. J Neuroimmunol (1997) 0.83
In vivo efficacy of azithromycin in treatment of systemic infection and septic arthritis induced by type IV group B Streptococcus strains in mice: comparative study with erythromycin and penicillin G. Antimicrob Agents Chemother (1995) 0.83
Low-dose streptozotocin-induced diabetes in mice. II. Susceptibility to Candida albicans infection correlates with the induction of a biased Th2-like antifungal response. Cell Immunol (1993) 0.82
Influence of interferon-gamma administration on the severity of experimental group B streptococcal arthritis. Arthritis Rheum (2000) 0.82
Dendritic cells, interleukin 12, and CD4+ lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide. Crit Rev Immunol (1998) 0.82
A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J Immunol (1997) 0.81
Involvement of the Th1 subset of CD4+ T cells in acquired immunity to mouse infection with Trypanosoma equiperdum. Cell Immunol (1992) 0.81
T helper cell dichotomy to Candida albicans: implications for pathology, therapy, and vaccine design. Immunol Res (1995) 0.81
Tolerance to staphylococcal enterotoxin B initiated Th1 cell differentiation in mice infected with Candida albicans. Infect Immun (1994) 0.80
Early T cell unresponsiveness in mice with candidiasis and reversal by IL-2: effect on T helper cell development. J Immunol (1997) 0.80
Biomolecular events involved in the establishment of brain anticandidal resistance. J Neuroimmunol (1996) 0.80